Covaxin: Indigenous Vaccine for COVID-19
Covaxin is India's first vaccine candidate to have gone into human clinical trials. It is developed by Bharat Biotech and has been approved by the Drug Controller General of India (DCGI) for phase I and II human clinical trials.
- The SARS-CoV-2 strain was isolated in National Institute of Virology (NIV), Pune and transferred to Bharat Biotech. They developed Covaxin as an “inactivated” vaccine — one made by using particles of the Covid-19 virus that were killed, making them unable to infect or replicate. Injecting particular doses of these particles serves to build immunity by helping the body create antibodies against ....
Do You Want to Read More?
Subscribe Now
Take Annual Subscription and get the following Advantage
The annual members of the Civil Services Chronicle can read the monthly content of the magazine as well as the Chronicle magazine archives.
Readers can study all the material before the last six months of the Civil Services Chronicle monthly issue in the form of Chronicle magazine archives.
Related Content
- 1 India-US Semiconductor Fabrication Agreement
- 2 UN Pact for the Future: Towards A New Era of Global Governance
- 3 Global Innovation Index 2024
- 4 Digital Agriculture Mission: A Step towards Transforming Farmers’ Lives
- 5 India-Singapore: Strengthening Bilateral Cooperation
- 6 SC Ruling on Sub-Classification of SCs & STs
- 7 Indian Carbon Market: Fulfilling Obligations of Paris Agreement
- 8 India-Austria: Boosting Bilateral Partnership
- 9 Supreme Court’s Ruling on States’ Taxation of Mining Activities
- 10 Climate Finance Taxonomy: Mobilising Investments towards a Sustainable Future
